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ABSTRACT
ObjectivesToevaluatetheriskofbiastool,introducedby
the Cochrane Collaboration for assessing the internal
validity of randomised trials, for inter-rater agreement,
concurrent validity compared with the Jadad scale and
Schulz approach to allocation concealment, and the
relation between risk of bias and effect estimates.
Design Cross sectional study.
Study sample 163 trials in children.
Main outcome measures Inter-rater agreement between
reviewers assessing trials using the risk of bias tool
(weighted κ), time to apply the risk of bias tool compared
with other approaches to quality assessment (paired t
test), degree of correlation for overall risk compared with
overall quality scores (Kendall’s τ statistic), and
magnitude of effect estimates for studies classified as
being at high, unclear, or low risk of bias
(metaregression).
Results Inter-rater agreement on individual domains of
the risk of bias tool ranged from slight (κ=0.13) to
substantial (κ=0.74). The mean time to complete the risk
of bias tool was significantly longer than for the Jadad
scale and Schulz approach, individually or combined (8.
8 minutes (SD 2.2) per study v 2.0 (SD 0.8), P<0.001).
There was low correlation between risk of bias overall
compared with the Jadad scores (P=0.395) and Schulz
approach (P=0.064). Effect sizes differed between
studies assessed as being at high or unclear risk of bias
(0.52) compared with those at low risk (0.23).
Conclusions Inter-rateragreement varied across domains
of the risk of bias tool. Generally, agreement was poorer
for those items that required more judgment. There was
low correlation between assessments of overall risk of
biasandtwocommonapproachestoqualityassessment:
the Jadad scale and Schulz approach to allocation
concealment. Overall risk of bias as assessed by the risk
of bias tool differentiated effect estimates, with more
conservative estimates for studies at low risk.
INTRODUCTION
Systematic reviews are considered the most compre-
hensive way of judging whether a treatment “does
more good than harm.”
1 The methodological quality
of studies included in a systematic review can have a
substantial impact on estimates of treatment effect,
which may affect the validity of the conclusions of a
review.
2 Careful consideration and appraisal of the
methodological characteristics of the primary studies
is an essential feature of systematic reviews. This
helps to identify areas of strength and weakness in the
existing evidence
3 and to formulate recommendations
to improve the conduct and value of future research.
Thetermsquality,validity,andbias
4havebeenused
interchangeably in the systematic review literature to
describemethodologicalconditionsthatareassociated
with the validity of study results. Traditionally, quality
assessment in systematic reviews has primarily
involved the appraisal of internal validity—how well
the study was designed and executed to prevent sys-
tematic errors or bias. Bias can result from flaws in
the design,conduct, analysis, interpretation, or report-
ingofa study.Inrandomisedcontrolledtrials,biashas
been classified into four general categories: selection,
performance, detection, and attrition.
5
Control of bias in randomised controlled trials is
necessary to reduce the risk of making incorrect con-
clusions about treatment effects.
6 Several empirical
studieshavedocumentedhowthelackofadequateran-
domisation, concealment of allocation, double blind-
ing,anddifferentiallossestofollow-upordropoutsper
treatment group may affect the observed treatment
effects.
57-11 Several meta-epidemiological studies have
examined the effect of certain methodological charac-
teristics and biases of individual randomised con-
trolled trials on the pooled estimates of meta-
analyses.
5712 Although the findings have been incon-
sistent across individual studies, evidence shows that
inadequate or unclear allocation concealment and
lack of double blinding lead to exaggerated estimates
of treatment effects.
The approach to quality assessment in systematic
reviews is inconsistent and often debated.
5 The uncer-
tainty about how quality measures are associated with
estimates of treatment effect and the absence of a gold
standardtoassessthevalidityofrandomisedcontrolled
trials
13haveresultedinthedevelopmentofalargenum-
berofqualityassessmenttools.
114Only12%oftheavail-
able scales and checklists to assess the methodological
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empirically evaluated.
14 Furthermore, these tools
1315
often contain elements attributable to reporting (for
example, whether the study population was described)
anddesign(forexample,whethera sample sizecalcula-
tion was carried out) that are not related to bias.
4
InFebruary2008theCochraneCollaborationintro-
ducedariskofbiastooltoassesstheinternalvalidityof
randomised controlled trials.
4 The tool was developed
toaddresssomeoftheshortcomingsofexistingquality
assessment instruments. Specifically, it was developed
to assess the degree to which the results of a study
“should be believed.”
4 The choice of components for
inclusion in the tool was based on empirical evidence
showingtheirassociationwitheffectestimates.
7816The
developers also aimed to distinguish between the
actual methods used for carrying out the randomised
controlled trials rather than the reporting.
The risk of bias tool is based on six domains:
sequence generation, allocation concealment, blind-
ing, incomplete outcome data, selective outcome
reporting, and “other sources of bias.” Critical assess-
ments on the risk of bias (high, low, unclear) are made
separately for each domain. A final overall assessment
within or across studies is based on the responses to
individual domains. The assessments are to be made
on the basis of the trial report as well as additional
documents,suchasthestudyprotocol.Thosecarrying
out the assessments are required to record the reasons
for their decisions. In this way the rationale for any
judgments is documented and transparent.
Although the use of the risk of bias tool has been
recommended for systematic reviews done within the
Cochrane Collaboration, it has not been validated for-
mally and it is unknown how the tool compares to
other approaches currently available to assess the
validity of a study. We evaluated the inter-rater agree-
ment of the risk of bias tool, the concurrent validity of
the tool compared with the Jadad scale
17 and Schulz
7
approach to allocation concealment, and the relation
between overall risk of bias as assessed by the risk of
biastooland studyeffectestimates.Wealsocompared
the time required to apply the risk of bias tool com-
pared with the Jadad scale and Schulz approach.
METHODS
Thiscrosssectionalanalyticalstudywascarriedouton
a convenience sample of 163 full manuscripts of ran-
domised controlled trials in child health; these manu-
scripts resulted from abstracts that were presented at
the annual scientific meetings of the Society for Pedia-
tric Research between 1992 and 1995. The trials were
part of a previously published project examining pub-
lication bias.
18 Their methodological quality had been
assessed previously using the Jadad scale and Schulz
approach to allocation concealment.
717 Likewise,
effect estimates for the primary outcome in each trial
had been extracted.
Tworeviewers(LH,MO)independentlyevaluateda
random sample of 80 randomised controlled trials to
assess the time to complete the risk of bias tool. This
preliminary evaluation also helped to develop some
guidelines for application of the tool to the entire sam-
ple of trials. One reviewer (NH) recorded the time
required to apply the Jadad scale and Schulz approach
to the same sample of 80 trials. Two reviewers (LH,
MO, DD, NH, or JS) independently applied the risk
of bias tool on the remaining trials after pilot assess-
ment and discussion of five trials among the group of
reviewers.
The primary outcome selected for each trial was
used for those items in the risk of bias tool that require
anoutcomefocusedevaluation—namely,blindingand
incomplete outcome data. We applied the tool based
on instructions in the Cochrane Handbook
4 and con-
sulted one of the developers of the tool (David
Moher) for clarification as needed. For the “other
sources of bias” domain, we assessed potential bias
due to baseline differences, inappropriate influence of
the study sponsor, and early stopping for benefit. For
crossover designs, we also considered whether such a
design was appropriate and whether the wash-out per-
iod was sufficient.
4 Overall risk assessments (high,
unclear, low) were based on the approach presented
in the Cochrane Handbook.
4
Analysis
We usedweighted κto assessinter-rater agreementfor
each domain of the risk of bias tool and for the final
overall assessment.
1920 We categorised agreement as
poor (0.00), slight (0.01-0.20), fair (0.21-0.40), moder-
ate (0.41-0.60), substantial (0.61-0.80), or almost per-
fect (0.81-1.00).
19 Correlations between domains of
the risk of bias tool, the Jadad scale, and Schulz
approach were calculated using Kendall’s τ statistic to
assess the concurrent validity of the risk of bias tool.
Wealsoassessedthedegreeofcorrelationfortheover-
all risk of bias assessment compared with the Jadad
overallscore,overallriskofbiasassessmentcompared
with the Schulz approach, and high or low risk as
assessed by risk of bias compared with low or high
quality as assessed by the Jadad overall score (<3 v
≥3
921). Using the paired t test we compared the time
to apply the risk of bias tool and time to apply the
Schulz approach and the Jadad scale.
EffectsizeswerecalculatedusingCohen’sdforcon-
tinuous outcomes; for dichotomous outcomes we con-
verted the odds ratios into effect sizes using a method
devised by Hasselblad and Hedges.
22 The effect sizes
were combined under DerSimonian and Laird ran-
dom effects model.
23 Statistical heterogeneity was
quantified using the I
2 statistic.
2425 We used meta-
regression to evaluate the effect of risk of bias on the
effectsizewhilecontrollingforpossibleconfoundersat
study level, including study type (efficacy v equiva-
lence), study design (crossover, factorial, or parallel),
and outcome type (binary v continuous, objective v
subjective). Studies were defined as efficacy versus
equivalence on the basis of the “authors’ statements
on the primary hypothesis.”
18 To determine outcome
type (objective v subjective), two reviewers (LH, SC)
classified the outcomes according to published
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26 and reached consensus through discus-
sion. Analyses were done using SAS version 9.1,
SPSS version 11.5, SPlus version 8.0 (Insightful, Seat-
tle, WA), and Intercooled Stata version 7.0.
RESULTS
Inter-rateragreement—Table 1showsthenumberofstu-
diesassessedashigh,unclear,orlowriskofbiasforthe
different risk of bias domains (see the web extra for
similar summary information for the Jadad scale and
Schulz approach to allocation concealment). Inter-
rater agreement for the individual domains of the risk
of bias tool ranged from slight (κ=0.13 for selective
reporting) to substantial (κ=0.74 for sequence genera-
tion, table 1). Discrepancies were largely driven by
reliance on reporting compared with judgment on
risk of bias. Hence domains that involved a greater
degree of subjective judgment about potential risk of
bias,suchasblinding,tendedtohavepoorerinter-rater
agreement than domains that were more objective,
such as sequence generation. For example, the same
level of blinding in a study could yield more or less
biased results for different outcomes: a hard end
point such as mortality may always be at low risk of
bias regardless of the extent of blinding; for a subjec-
tive outcome such as quality of life, bias may be more
likely if blinding of patients and caregivers was
inadequate. Table 2 itemises some of the sources of
discrepancies and recommendations on how these
might be tackled.
Timeforriskofbiasversusqualityassessment—Themean
total time to complete the risk of bias tool by two
reviewers (including consensus) for a single outcome
was20.7minutes(SD7.6;range11-58minutes).Based
on a sample of 80 trials the mean time for a single
reviewer to complete the risk of bias tool was
8.8 minutes (SD 2.2) compared with 0.5 minutes
(SD 0.3) for the Schulz approach (P<0.001),
1.5minutes (SD0.7)fortheJadadscale(P<0.001),and
2.0minutes(SD0.8)fortheSchulzapproachandJadad
scale combined (P<0.001).
Concurrentvalidityofriskofbiastool—Ahighdegreeof
correlation was found between the domains of risk of
bias sequence generation comparedwith Jadad rando-
misation, risk of bias allocation concealment com-
pared with Schulz allocation concealment, and risk of
bias blinding compared with Jadad double blinding
(table 3). Correlation was low for the comparisons
between the domains of risk of bias incomplete out-
come data and the Jadad withdrawal item, risk of bias
overallriskand totalJadadscore,andriskofbiasover-
all risk and Schulz allocation concealment (table 3).
Relation between risk of bias and magnitude of effect esti-
mates—Effectestimateswerelargerforstudiesassessed
ashavinghighorunclearriskofbias(high,n=61,effect
size 0.52, 95% confidence interval 0.37 to 0.66;
unclear,n=96,effectsize=0.52,0.39to0.64)compared
with those with low risk of bias (n=6, effect size 0.23,
−0.16 to 0.62; figure). Several potential confounders
were controlled for through metaregression. The only
variablethatwasstatisticallysignificantwasstudytype
—efficacy versus equivalence. The trend for efficacy
studies was similar to all studies combined, where stu-
dies with high and unclear risk of bias had larger effect
sizes thanthose withlow risk of bias(high, n=47, effect
size 0.69, 0.50 to 0.87; unclear, n=79, effect size 0.64,
0.50to0.78;low,n=5,effectsize0.34,−0.10to0.78).A
reverse pattern was observed for equivalence studies,
where those with high or unclear risk of bias were clo-
ser to the null compared with those of low risk (high,
Table 2 |Sources of discrepancies and recommendations for selected domains of risk of bias tool
Domain Source of discrepancy Recommendation
Blinding Previous tools judge this domain on basis of reporting. In risk of bias tool,
reviewers make judgment on potential risk of bias associated with level of
blinding depending on nature of outcome
Identifyoutcomes(orgroupsofoutcomes)tobeassessedbythisdomainapriori;
develop guides for interpretation and application of this domain on basis of
nature of intervention and outcomes chosen for review
Incomplete data Previous tools judge this domain largely on reporting. In risk of bias tool,
reviewers make judgment on extent of withdrawals,reasons, and whether these
two factors are likely to yield biased results
Identifyoutcomes(orgroupsofoutcomes)tobeassessedbythisdomainapriori;
develop guides for interpretation and application of several factors—proportion
of withdrawals or dropouts from overall sample, reasons for withdrawals or
dropouts, and whether reasons and extent of withdrawals or dropouts were
different across study groups
Selective reporting Ideally, outcomes planned for study (in study protocol)would becompared with
those that were analysed and reported. The search and identification of study
protocols may not be fruitful or feasible
In absence of protocols or resources to locate protocols for each included trial,
outcomes described in methods section to be compared with those reported in
results.Studiesthatreportfewoutcomesmayalsobeatriskofselectivereporting
bias. A priori, identify key outcomes that should be reported for particular
intervention and patient population
Other sources of bias Some of these include early stopping, baseline imbalance, differential
diagnostic activity, contamination; some are based on trial design (for example,
crossover, cluster, factorial). These items will vary according to context and
studies relevant to given systematic review
Reviewers should decide a priori which “other sources of bias” will be assessed
and develop guides for interpretation. Consideration should always be given to
whether there were differences across groups in important variables at baseline;
whether authors declared their source of funding; and whether trial was stopped
early because benefit was shown
Table 1 |Inter-rater agreement using risk of bias tool
Domain
Risk of bias assessments
Weighted κ (95% CI) High Unclear Low
Sequence generation 4 107 52 0.74 (0.64 to 0.85)
Allocation concealment 5 105 53 0.50 (0.36 to 0.63)
Blinding 16 49 98 0.35 (0.22 to 0.47)
Incomplete data 25 52 86 0.32 (0.19 to 0.45)
Selective reporting 16 19 128 0.13 (−0.05 to 0.31)
Other sources of bias 15 85 63 0.31 (0.17 to 0.44)
Overall risk of bias 61 96 6 0.27 (0.13 to 0.41)
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effect size −0.08, −0.30 to 0.15; low: n=1, effect size
−0.32, −0.88 to 0.25).
DISCUSSION
We applied the Cochrane risk of bias tool to a sample
of 163 randomised controlled trials in children.
Despite guidance from the Cochrane Handbook on how
to apply the tool, the overall inter-rater agreementwas
fair. Our results stemmed from application of the tool
by reviewers working in the same institution and
reviewteam.Morevariabilityacrossdifferentresearch
groupsmightbeexpected.Thishighlightstheneedfor
clear and detailed instructions to optimise reliability.
Much of the disagreement arose from items requir-
ing judgment on the potential risk of bias given the
methods or approaches described in a study. This
underscores the need to establish clear guidelines at
the outset of a review and to carry out pilot testing
with a sample of studies that are representative of the
review question or clinical area. In future research we
will examine whether decision rules can reduce inter-
rater variability.
We found that the ratings for many domains of the
risk of bias tool were “unclear.” This may reflect the
nature of the domain or the insufficient reporting of
study methods and procedures. In some cases the
assessment of “unclear” resulted from poor reporting
at the individual study level. While reporting may
improve for more recent studies as journals and
authors adopt the consolidated standards of reporting
trials (CONSORT) guidelines,
27 systematic reviewers
will continuetofaceissuesarisingfrompoorreporting
when they include studies from the era before the
guidelines.
On average it took experienced reviewers less than
10minutestoindependentlyapplythetoolforasingle,
predetermined outcome. The time required to com-
plete the assessments may decrease with increased
familiarity and use of the tool. However, more time
will be required to apply the risk of bias tool in the
context of a full systematic review, as assessments
should be made for all main outcomes or classes of
outcomes.
4 Furthermore, the Cochrane Handbook
recommendsthat studyprotocolsare soughttoinform
or verify judgments.
4 This would further increase the
time required to complete the risk of bias assessment.
The correlation between the risk of bias tool and the
Schulz or Jadad approaches was significant in some
domains (sequence generation or randomisation, allo-
cation concealment, blinding) but not others (missing
data, overall scores). Higher correlations were
obtained in domains that were most similar among
the different tools. For example, the Jadad item evalu-
ating whether the randomisation sequence was ade-
quately generated is similar to the sequence
generation domain of the risk of bias tool. The lack of
correlation for the missing data domain seems to be
due to the emphasis on reporting in the Jadad instru-
ment compared with conduct in the risk of bias tool—
that is, how missing data were handled.
The lack of a significant correlation between the
overall risk of bias and Jadad scale, and the risk of
bias and Schulz approach, may reflect the different
dimensions evaluated by the instruments. The risk of
bias tool measures several domains that contribute to
the overall assessment of risk of bias, including alloca-
tion concealment, and also incorporates selective out-
come reporting and “other sources” of bias, domains
that are not assessed by the Jadad scale. The lack of
correlation could also be explained by the difference
in how assessments are made—that is, the reliance on
Table 3 |Correlation between domains and overall risk as assessed by risk of bias tool compared with Jadad scale and
Schulz approach to allocation concealment
Comparison Kendall’s τ
Comparison of domains:
Risk of bias sequence generation (yes/no/unclear) v Jadad randomisation (bonus/deduction) 0.788
Risk of bias allocation concealment (yes/no/unclear) v Schulz allocation concealment (adequate/inadequate/unclear) 0.729
Risk of bias blinding (yes/no/unclear) v Jadad double blinding (bonus/deduction) 0.219
Incomplete outcome data (yes/no/unclear) v Jadad withdrawals −0.09
Comparison of overall risk or “quality”:
Risk of bias overall risk (high/unclear/low) vs. Jadad (0-5) 0.059
Risk of bias overall risk (high or unclear/low) v Jadad (0-2/3-5) 0.085
Risk of bias overall risk (high/unclear/low) v Schulz allocation concealment (adequate/inadequate/unclear) 0.138
All
  High
  Unclear
  Low
Efficacy
  High
  Unclear
  Low
Equivalence
  High
  Unclear
  Low
0.52 (0.37 to 0.66)
0.52 (0.39 to 0.64)
0.23 (-0.16 to 0.62)
 
0.69 (0.50 to 0.87)
0.64 (0.50 to 0.78)
0.34 (-0.10 to 0.78)
 
0.06 (-0.06 to 0.17)
-0.08 (-0.30 to 0.15)
-0.32 (-0.88 to 0.25)
61
96
6
47
79
5
14
17
1
-1 -0.5 0 0.5 1
Group
Favours
control
Favours
treatment
Effect size
(95% CI)
Effect size
(95% CI)
No of
studies
Effect size estimates according to risk of bias
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with the risk for biased results given the methods that
wereused.Thelackofcorrelationsuggeststhatthedif-
ferent tools are measuring different constructs; hence,
theriskofbiastoolmaybemoreappropriateforasses-
sing a trial’s internal validity.
Several studies have provided empirical evidence
showing that trials with methodological flaws may
overestimatetreatmenteffects.Thishasbeenobserved
for allocation concealment,
791128 sequence
generation,
729 double blinding,
7 handling of missing
data,
3031 and selective reporting of outcomes.
163233
Weevaluatedtheriskofbiastoolandshoweditsability
to differentiate between trials that may have overesti-
mated treatment effects. Our results show that studies
assessed as at high or unclear risk of bias have larger
effectestimatesthanstudieswithalowriskofbias.The
pattern was consistent for efficacy studies, whereas the
reverse pattern was observed for equivalence studies.
These results should be considered cautiously given
the small number of studies, particularly in the refer-
ence category. More rigorous statistical methods that
minimiseconfoundingduetointerventionanddisease
are required to confirm these findings. Nevertheless,
the results provide some preliminary validation on
the usefulness of the risk of bias tool to identify studies
that may exaggerate treatment effects. This is particu-
larly relevant to systematic reviewers as well as any
practitioner who wants to assess the potential impact
of an intervention.
Limitations of the study
This study has several limitations. For efficiency we
used information that was generated as part of a pre-
vious study—namely, data on effect size; selection of a
single, prespecified outcome; and previous assess-
ments using the Jadad and Schulz approaches.
18 As
such a delay occurred between application of the
three instruments; moreover, the tools were applied
by a different team of researchers. This may have con-
tributed to some variability in the application and
interpretation of these assessment tools and possibly
attenuated the observed correlations; however, it is
likely that this more closely resembles the use of
these tools in real settings. We applied the risk of bias
tool to a single outcome, which is not the recom-
mended approach. This may have resulted in some
studies being rated differently for overall risk of bias
than if we had considered all of the main or important
outcomes. Although we found significant differences
in effect sizes when comparing studies at high or
unclear risk of bias with those at low risk, these were
basedonsmallnumbersoflowriskstudies(sixintotal)
and the confidence interval for such studies was wide.
Assessing a more recent sample of studies after the
implementation of the CONSORT guidelines may
increase the number of low risk studies and may pro-
videamorecertainestimateoftheimpactofriskofbias
on effect size. Furthermore, the studies in our sample
were published before the release of the CONSORT
statement,which may have resulted in more “unclear”
assessments than may be the case for more recently
published studies. The sample of trials was hetero-
geneous for outcomes, interventions, and diseases;
this differs from the hallmark meta-epidemiological
studies in this area that have evaluated the relation
between methodological characteristics and effect
estimates.
3435 We used effect sizes to standardise the
measures of effect so that we could look at general pat-
terns across studies with different risks of bias. Finally,
the sample included only trials in children and there-
fore the results may not be generalisable to other areas
of health care.
Conclusions
We found substantial variation in agreement across
domains of the risk of bias tool. Generally the items
with poor inter-rater agreement were those that
required substantial judgment about the potential for
the study methods to yield biased results. There was
low correlation between overall assessments using the
riskofbiastoolcomparedwiththetwocommonlyused
tools: the Jadad scale and the Schulz approach to allo-
cationconcealment.Overallriskasassessedbytherisk
of bias tool differentiated effect estimates, with more
conservative estimates for low risk studies. Careful
training and clear guidelines are required when apply-
ing the tool.
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